# Operational Outcomes of Propofol Sedation versus Fentanyl, Midazolam and Diphenhydramine Sedation for Endoscopies and Colonoscopies at an Academic Medical Center



A Mariotti, MHA.<sup>1</sup>, C Lace MD<sup>2</sup>, A Brown, BSN RN<sup>3</sup>, S Rist, BS<sup>4</sup>, S Edmundowicz, MD<sup>3</sup>, T Hardesty RN BSN MBA<sup>3</sup>, M Lemley, MD<sup>2</sup>, N Weitzel, MD<sup>2</sup>, J Pattee, PhD<sup>5</sup>, AA Faruki, MD<sup>2</sup>

<sup>1</sup>University of Colorado School of Medicine, Aurora, CO., <sup>2</sup>Department of Anesthesiology, University of Colorado Hospital, Aurora, CO.,

<sup>3</sup>Department of Gastroenterology, University of Colorado Hospital, Aurora, CO., <sup>4</sup>UCHealth, Aurora, CO., <sup>5</sup>Colorado School of Public Health, Aurora, CO

# Background


- 51.5 million gastrointestinal endoscopies are performed annually in the United States and are predicted to grow at an annual rate of 2.6%. A
- University of Colorado Hospital (UCH) Department of Anesthesia implemented Monitored Anesthesia Care (MAC) for sedation of gastrointestinal procedures in place of Nurse Administered Sedation (NAS) on 7/1/21.

MAC Sedation: propofol without adjuncts NAS: IV fentanyl, midazolam, diphenhydramine

- Consenting by GI proceduralists shifted from in-procedural suite to in-preoperative area to improve patient flow on 7/1/21.
- We hypothesize that MAC will improve operational outcomes as compared to NAS.

## Methods

- A COMIRB approved, retrospective, single-cohort analysis using STROBE guidelines.
- Inclusion criteria was based on sedation type (MAC or NAS), abstracted from the UCH EMR, and analyzed using a two-sample t-test.
- Significant comorbidities assessed: obstructive sleep apnea, asthma, coronary arterial disease, GERD, hepatic dysfunction, hypertension, kidney disease, liver disease, pulmonary hypertension, renal disease, and valvular heart disease.
- Primary and secondary outcome measures will include:
  - 1. Sedation Start to Scope-In (SSSI): Time sedation begins to time scope is placed
- 2. In-room to Scope-in (IRSI): Time patient enters procedural suite to time scope is placed
- 3. Total Case Length (TCL): Time patient enters procedural suite to time patient exits suite
- 4. Scope-Out to Out of Room (SOOR): Time sedation ends to time patient exits procedural suite
- 5. PACU Length of Stay (PACU LOS): Time patient enters PACU to time patient exits PACU



# Results

\*p-values ≤ 0.05 are statistically significant

Table 2: Evaluation of Primary Outcome

×	NAS (n=4606)	MAC (n=1034)
Female	2459 (53%)	555 (54%)
Male	2147 (47%)	479 (46%)
<b>e</b> (years)	(,3)	- (.0,0)
18-29	287 (6.3%)	64 (6.2%)
30-49	1090 (24%)	248 (24%)
50-64	1833 (40%)	397 (38%)
≥65	1396 (30%)	325 (31%)
ody Mass Index (BMI)		
<18.5	92 (2%)	21 (2%)
18.5-24.9	1651 (36%)	399 (39%)
25.0-29.9	1643 (36%)	355 (34%)
≥30	1158 (25%)	258 (25%)
omorbidities		
0-1	3735 (81%)	834 (80%)
2-4	848 (18%)	194 (19%)
≥5	23 (0.5%)	6 (0.5%)
ocedure Type		
Upper GI	1202 (26%)	234 (23%)
Lower GI	3070 (67%)	704 (68%)
Combined	334 (7.3%)	96 (9.3%)

### **Sedation Start to Scope-in** NAS Difference MAC P-value 9.95 (3.69) 0.0000\* 7.56 (3.69) Upper GI 0.0000\* 9.45 (3.57) 7.34 (3.00) - 2.11 Lower G 0.0000\* 9.93 (3.60) 7.84 (3.40) Combined Table 3: Evaluation of Secondary Outcomes In Room to Scope in Time NAS P-value **Difference** MAC 31.76 (15.57) 10.34 (10.16) 0.0000\* - 21.42 Upper GI 29.39 (15.35) 9.94 (9.32) 0.0000\* - 19.45 Lower Gi 10.00 (8.55) 0.0000\* 30.31 (15.96) Combined **Total Case Length** lean minutes (SD) 44.25 (17.40) 23.07 (13.77) 0.0000\* - 21.18 Upper GI 0.0000\* - 20.71 54.83 (18.69) 34.12 (14.18) 0.0000\* 67.89 (19.48) 48.17 (14.29) - 19.72 Combined Scope-Out to Out of Room 4.92 (5.45) 4.05 (7.19) 0.0815 Upper GI 4.16 (5.27) 3.57 (5.49) 0.0089\* Lower GI 4.08 (3.22) PACU Length of Stay

48.77 (31.56)

41.57 (21.37)

50.30 (25.98)

Upper GI

Lower GI

Combined

0.0003\*

0.0212\*

0.4473

- 2.11

- 2.07

41.76 (25.68)

39.46 (22.02)

48.23 (22.66)

### Conclusions

- Primary and secondary outcomes demonstrate MAC sedation at UCH is more operationally efficient than NAS.
- Statistically significant decreases in SSSI and PACU LOS were a result of changes in sedation depth and medications between MAC sedation and NAS. Statistically significant decreases in IRSI were a result of changes to both sedation and consenting procedures during preop.
- TCL decreased as a result of decreases in all outcomes.
- SSSI was chosen as the primary outcome for its direct correlation to the change in sedation technique. Secondary outcomes were a result of both sedation technique changes and improvements to process flow.

## **Implications**

- Decreased SSSI in combination with decreased secondary outcomes allows for increase in number of GI procedures per day. This results in improved access to care which studies have shown can reduce patient morbidity and mortality. B
- There is opportunity for other service lines to adopt MAC sedation for enhanced efficiency and increased access to more health services.

# No Disclosures

## References

<sup>A</sup> Tan, George, and Satish S.C. Rao. "Part I: How to Ergonomically Design a Modern Endoscopic Suite." Techniques in Gastrointestinal Endoscopy, vol. 21, no. 3, 2019, pp. 133–139., https://doi.org/10.1016/j.tgie.2019.07.001.

<sup>B</sup> Prentice, Julia C, and Steven D Pizer. "Delayed access to health care and mortality." Health services research vol. 42,2 (2007): 644-62. doi:10.1111/j.1475-6773.2006.00626.x